Editas Medicine Expands Leadership Team with Key Organizational Appointments

Editas Medicine Expands Leadership Team with Key Organizational Appointments

January 5, 2016

Cambridge, Mass., January 5, 2015 – Editas Medicine, a leading genome editing company, today announced the appointment of Timothy D. Hunt as senior vice president of corporate affairs and Haiyan Jiang, Ph.D., as vice president of preclinical science.

Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial of SEL-212, Designed to be the First Non-Immunogenic Biologic Treatment for Gout

Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial of SEL-212, Designed to be the First Non-Immunogenic Biologic Treatment for Gout

December 23, 2015

Watertown, Mass. – December 23, 2015 – Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune therapies, today announced the dosing of the first patient in the Company's Phase 1b clinical trial to assess the safety, pharmacodynamic profile and efficacy of SEL-212, Selecta's proprietary biologic treatment for refractory and tophaceous gout.

Black Duck Names Jukka Alanen VP of Business Development and Corporate Strategy

Black Duck Names Jukka Alanen VP of Business Development and Corporate Strategy

November 24, 2015

BURLINGTON, MA - November 24, 2015 – Black Duck Software, a global leader in automated solutions for securing and managing open source software, today announced the appointment of Jukka Alanen as its Vice President of Business Development and Corporate Strategy.

Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Beta-Thalassemia Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Beta-Thalassemia Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

December 11, 2015

SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced preliminary results from two Phase 2 clinical trials of luspatercept in patients with beta-thalassemia were presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition.

Agios Pharmaceuticals, Inc.

Agios Announces Initiation of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients

Agios Announces Initiation of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients

December 18, 2015

CAMBRIDGE, Mass., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals Inc., (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the initiation of a Phase 1b, multicenter, international, open-label study of AG-221 or AG-120 in combination with induction and consolidation therapy in patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase (IDH) mutation who are eligible for intensive chemotherapy.

Seres Therapeutics Announces Initiation of a Phase 1b Clinical Trial of SER-287 in Mild-to-Moderate Ulcerative Colitis

Seres Therapeutics Announces Initiation of a Phase 1b Clinical Trial of SER-287 in Mild-to-Moderate Ulcerative Colitis

December 14, 2015

CAMBRIDGE, Mass. (BUSINESS WIRE)--Dec. 14, 2015--Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that it has initiated a Phase 1b clinical trial evaluating SER-287 in mild-to-moderate ulcerative colitis (UC). The program IND has been cleared by the FDA, and clinical investigational sites are now open and actively enrolling patients. SER-287 is the first microbiome therapeutic candidate to reach clinical-stage development in a chronic disease, and the first in an indication outside of infectious disease.

BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer

BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer

December 16, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS(R), today announced the appointment of Jonathan Yingling, Ph.D., as Chief Scientific Officer. In this position, Dr. Yingling will be responsible for leading BIND's research and development efforts to identify and pursue new product opportunities where the unique attributes of ACCURINs can be leveraged to provide meaningful improvements in patient care.

BIND Therapeutics to Advance BIND-014 Squamous Histology Non-Small Cell Lung Cancer Cohort to Second Stage of iNSITE 1 Trial

BIND Therapeutics to Advance BIND-014 Squamous Histology Non-Small Cell Lung Cancer Cohort to Second Stage of iNSITE 1 Trial

December 14, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS(R), today announced that the squamous histology non-small cell lung cancer (NSCLC) cohort of the phase 2 iNSITE 1 trial will advance to the second stage and complete enrollment to 40 patients. The company also announced that the KRAS mutant NSCLC arm will not advance to the second stage.

Dr. Elizabeth Nabel Joins Moderna Therapeutics’ Board of Directors

Dr. Elizabeth Nabel Joins Moderna Therapeutics’ Board of Directors

December 15, 2015

CAMBRIDGE, Mass., December 15, 2015 — Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics (TM), announced today that Elizabeth (Betsy) Nabel, M.D., President of Harvard-affiliated Brigham and Women's Health Care (BWHC) has been appointed to the company's Board of Directors.

FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes

FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes

December 11, 2015

BUSINESS WIRE--Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to luspatercept for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (MDS). The Fast Track program of the FDA is designed to facilitate the development, and expedite the review, of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.